A policy change expanding Medicare coverage for GLP-1 treatments would dramatically increase access for seniors, but observers warn the approach needs stronger integration with broader weight management strategy. The piece argues that simply widening coverage without a “holistic” framework adds risk. The discussion matters for manufacturers and payers because GLP-1 demand is tightly linked to eligibility rules, prescriber behavior, and how programs address comorbidities and long-term adherence. For the sector, the policy direction highlights the importance of coverage design as much as drug efficacy—especially when uptake scales beyond current prescribing patterns.